Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
Press Releases 2020
Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
-
Tue, 15-Dec-2020
- Posted by: Biocon Biologics
No Comments
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs
-
Sat, 07-Nov-2020
- Posted by: Biocon Biologics
Biocon Ranked Among Top 5 Biotech Employers Globally
-
Fri, 30-Oct-2020
- Posted by: Biocon Biologics
Biocon Q2FY21 Revenue at Rs 1,760 Cr, Up 10%; EBITDA at Rs 407 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr; Generics Up 8% at Rs 599 Cr; Biosimilars Up 11% at Rs 676 Cr; Research Services Up 12% at Rs 520 Cr.
-
Fri, 23-Oct-2020
- Posted by: Biocon Biologics
Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
-
Thu, 08-Oct-2020
- Posted by: Biocon Biologics
Biocon Biologics to Roll Out ‘Mission 10 cents’ in Philippines; Signs MoU with 2 Municipal Governments & reach52 to enable Affordable Access to Quality Insulins
-
Wed, 30-Sep-2020
- Posted by: Biocon Biologics
Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
-
Mon, 31-Aug-2020
- Posted by: Biocon Biologics
Tata Capital Growth Fund to Invest ~USD 30 million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85% Deal Values Biocon Biologics at USD 3.5 Billion.
-
Fri, 31-Jul-2020
- Posted by: Biocon Biologics
Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr
-
Thu, 23-Jul-2020
- Posted by: Biocon Biologics
Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
-
Tue, 21-Jul-2020
- Posted by: Biocon Biologics
